Friday 6 November 2026 Export INCY’s income statement to Excel — free account

Incyte Corporation

INCY Healthcare Biotechnology

Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024.

Revenue: +14.0%
EPS: −277.9%
Free cash flow: −233.0%
Total debt: −10.5%

Quarter to September 2026, against a year earlier

119.22 1.21 +1.03%

Follow INCY

Alert me

Market cap: $24.1B
P/E: 56.3×
Fwd P/E: 55.6×
Dividend yield: —
F-score: 9/9
Altman Z: 8.57
Beneish M: −2.43
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Incyte Corporation 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed Oct 29, 2026 · accepted 4:03 PM ET · Document on sec.gov · Filing index

Red flags

Inventory outpacing revenue Oct 29, 2026
Inventory grew 60.9% while revenue grew 14.0% year over year

10-Q filed Oct 29, 2026 · The filing · sec.gov

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Previous quarter Same quarter last year

Part I, Item 2, Management’s Discussion and Analysis, against the 10-Q filed Jul 28, 2026: 7 added · 6 removed · 46 modified; 6 with only figures updated

Modified · Forward-Looking Statements

•future required expertise relating to ~~clinical trials~~development, manufacturing, sales and marketing;

Incyte Corporation 10-Q filed Oct 29, 2026

Red flags

What changed

Stockrow Weekly